ClinicalTrials.gg
CompletedNCT06540807Updated May 20, 2026Results posted

SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study

An interventional study of Colovac Colorectal Anastomosis Protection Device and Stoma creation in Colorectal Cancer, sponsored by SafeHeal Inc. Completed at 1 site in Uzbekistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by SafeHeal Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A feasibility study to assess the early safety and effectiveness of the Colovac 2 device in providing temporary protection of the anastomosis in patients undergoing low anterior resection for colon cancer.

Read the detailed description

A primary diverting stoma is widely used by surgeons to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.

Colovac is a local, temporary, minimally invasive bypass device that protects the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac allows stoma avoidance in all patients except those whose anastomosis have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.

02

Conditions studied

  • Colorectal Cancer
03

In context

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's enrollment of 24 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

SafeHeal Inc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for , based on multidisciplinary team recommendations
  • (ECOG) Performance Status ≤ 2History of left sided colitis
  • Willingness to comply with protocol-specific treatment and study visits and to sign a written Form

Exclusion criteria

Exclusion Criteria:

  • History of left sided colitis
  • Known allergy to nickel or other components of the Colovac 2 System
  • Pregnant or nursing female subject
  • Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy)
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results including, but not limited to:
  • Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease
  • Immunodeficiency ( \< 500 CU MM)
  • Systemic therapy within the past 6 months
  • Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery
  • Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
  • Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis
  • Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging
  • Severe malnutrition which is defined as at least 10% weight loss within 3 months prior to enrollment.
  • Occurrence of any of the following during the colorectal surgery:

    1. Blood loss (>750 cc)
    2. Blood transfusion
    3. Any new sign of ischemia
    4. Positive air leak test
    5. Inadequate bowel preparation
    6. Anastomosis location greater than 15 cm from the anal verge
    7. Other intra-operative risks that preclude the subject from undergoing the procedure with the device
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Colovac

    The Colovac device will be implanted for approximately 10 days.

    Device: Colovac Colorectal Anastomosis Protection Device · Procedure: Stoma creation

Interventions

  • DeviceColovac Colorectal Anastomosis Protection Device

    A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)

    Also known as: Colovac 2

  • ProcedureStoma creation

    Diverting loop ileostomy

06

What researchers measure

Primary outcomes

  1. Migration

    Rate of clinically significant device migration The rate of subjects for which the device has migrated clinically significant during its 10-day implant period.

    Time frame: 10 days

07

Results

Posted May 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneColovac
Started24
Completed24
Not completed0

Outcome measures

PrimaryMigration

Rate of clinically significant device migration The rate of subjects for which the device has migrated clinically significant during its 10-day implant period.

Time frame:
10 days
Reported as:
Count of participants · Participants
Migration
ParticipantsColovac
Migration2

Adverse events

Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Colovac0/24 (0%)4/24 (16.7%)3/24 (12.5%)
Most frequent serious events
Most frequent serious events
EventColovac
Anastomotic LeakGastrointestinal disorders4/24
BleedingGeneral disorders1/24
Most frequent other events
Most frequent other events
EventColovac
FeverGeneral disorders3/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Colovac
Mean56 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Colovac
Female11
Male13
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Colovac
Region of Enrollment
Region of Enrollment(participants)Colovac
Uzbekistan24
08

Study locations

1 site
  • AKFA
    Tashkent, Uzbekistan
09

References and documents

Publications

  • Lefevre JH, Karachun A, Sametdinov N, Raximov O, Rustamov A, Adilkhodjaev A, Yunusov S, Mirzagolib T, Sylla P. Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study. Surg Endosc. 2026 May;40(5):4126-4135. doi: 10.1007/s00464-026-12691-y. Epub 2026 Mar 5. PubMed 41787083 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Mar 2025, 7 months.

Results were first posted in May 2026, 1 year 2 months after primary completion.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 7 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 6, 2024
StartActual
Jul 31, 2024
Primary completionActual
Mar 6, 2025
CompletionActual
Dec 26, 2025
Results first posted
May 20, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06540807
Lead sponsor
SafeHeal Inc
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Jul 31, 2024
Primary completion
Mar 6, 2025
Completion
Dec 26, 2025
Results posted
May 20, 2026
Last update
May 20, 2026

Study contacts

Okiljon Rahimov, MD
principal investigator · Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology MoH of RUz
Narxodja Sametdinov, MD
principal investigator · Akfa Medline LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion